Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
Graviton BioScience announced publication of positive Phase 1b results for GV101 (TDI01) in chronic Graft versus Host Disease, reporting an 86.2% best overall response rate at the 400 mg dose. The trial of 60 patients showed failure-free survival of 89.4% at 24 weeks with a favorable safety profile and no evidence of hematopoietic toxicity. Graviton, led by CEO Dr.
Key figures
- Drug Name
- GV101 (TDI01)
- Phase Of Trial
- Phase 1b
- Ffs 200mg
- 78.6%
- Ffs 400mg
- 89.4%
- Borr 200mg
- 67.9%
- Borr 400mg
- 86.2%
- Patients enrolled
- 60
- Median time to response 200mg
- 44.5 days
- Median time to response 400mg
- 30.0 days
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.